IDEAYA and Pfizer to evaluate combo of IDE196 and binimetinib

18 March 2020

US precision medicines company IDEAYA Biosciences (Nasdaq: IDYA) saw its shares leap 15.5% to $3.50 by mid-day, after it revealed a clinical trial collaboration with pharma giant Pfizer (NYSE: PFE).

The companies plan for an IDEAYA-sponsored clinical combination study of IDE196, a protein kinase C (PKC) inhibitor, and binimetinib, a MEK inhibitor that Pfizer has exclusive rights to in the USA and Canada, in GNAQ or GNA11 hotspot mutated solid tumors, including metastatic uveal melanoma (MUM), cutaneous melanoma and colorectal cancer (CRC).

IDEAYA and Pfizer will form a joint development committee (JDC), and there will be joint decision making and data sharing of the clinical trial results between the parties. IDEAYA will sponsor the study and Pfizer will supply binimetinib for the study. The clinical combination trial is targeted to initiate in mid-2020. No financial terms of the deal were disclosed.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK